INBS logo

INTELLIGENT BIO SOLUTIONS IN

INBSNASDAQ
🏆 #5154 by market capUS Equity
$129.41▲ $9.80 (+7.57%)
Simulated price
🔔
Track INBS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.6%
7d▲ 7010.4%
14d▲ 6212.7%
30d▲ 5600.9%
ytd▲ 1260.8%
1y▲ 1035.2%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
+38.1%
High Growth
📊Gross Margin
48.6%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
1.3x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$127.42 – $131.77
52-Week Range
$1.52 – $24.90
Volume
$1.69B
Avg Volume
$1.55B
Shares Outstanding
2.4M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
1.3x
EPS (TTM)
$-9.66
Dividend Yield
—
Dilution (1yr)
+205.6%

Why Investors Own INBS

  • ✓High-growth profile — revenue up +14.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 64% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

INBS logo

INTELLIGENT BIO SOLUTIONS IN

INBS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▲ +38.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
48.6%▲ +19.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +18.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$12M▲ +21.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.9M▲ +205.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▲ +$5M YoY
StockOtter · stockotter.space

About INTELLIGENT BIO SOLUTIONS IN

Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$127.57
▼ −1.4% Downside
High Target$154.63
Low Target$104.68
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

INTELLIGENT BIO SOLUTIONS IN tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift INBS price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

INTELLIGENT BIO SOLUTIONS IN announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.